Pzena Investment Management, Inc.
+6.68%
3个月收益率
$22.130
+0.606 (+2.74%)收盘时
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
Fresenius Medical Care AG is not a good buy right now. The current price is $21.06, and the RSI is at 31.076, indicating oversold conditions. However, the forward P/E ratio is 8.5763, suggesting potential undervaluation, but the recent downgrades from analysts and a significant 23.17% decline over the past year raise concerns. The main risk is the potential for further declines in U.S. dialysis volumes, as indicated by BNP Paribas's downgrade.

Berkshire Hathaway Reduces DaVita Holdings

Focus Graphite Secures C$2 Million Credit Facility to Enhance Working Capital

Fresenius Medical Care Q2 2026 Earnings Call Insights

Fresenius Medical Care Reports Strong Q2 Growth

Fresenius Medical Care Q2 Earnings Highlights
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.
Fresenius Medical Care AG is not a good buy right now. The current price is $21.06, and the RSI is at 31.076, indicating oversold conditions. However, the forward P/E ratio is 8.5763, suggesting potential undervaluation, but the recent downgrades from analysts and a significant 23.17% decline over the past year raise concerns. The main risk is the potential for further declines in U.S. dialysis volumes, as indicated by BNP Paribas's downgrade.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。